Cargando…
JAK1 inhibitor abrocitinib for the treatment of steroid-induced rosacea: case series
BACKGROUND: Steroid-induced rosacea is a severe withdrawal reaction which can occur after the frequent and excessive topical use of steroids on the face. The Janus kinase (JAK)-signal transducers and activators of transcription signaling pathway is involved in many biological processes and may play...
Autores principales: | Xu, Bingyang, Xu, Zining, Ye, Shuhong, Sun, Hong, Zhao, Bin, Wu, Na, Wu, Jiawen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505430/ https://www.ncbi.nlm.nih.gov/pubmed/37724178 http://dx.doi.org/10.3389/fmed.2023.1239869 |
Ejemplares similares
-
Successful Treatment of Granulomatous Rosacea by JAK Inhibitor Abrocitinib: A Case Report
por: Ren, Mingyang, et al.
Publicado: (2023) -
A study of the efficacy and safety of plaque psoriasis treatment by TNF‐α and IL‐17A inhibitor biologics in patients who received the inactivated SARS‐CoV‐2 vaccine
por: Ye, Shuhong, et al.
Publicado: (2023) -
Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis
por: Iznardo, Helena, et al.
Publicado: (2023) -
Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib
por: Nezamololama, Novin, et al.
Publicado: (2020) -
Abrocitinib: First Approval
por: Deeks, Emma D., et al.
Publicado: (2021)